What clinical trials has miltefosine been studied in (and for which diseases)?
Miltefosine is an oral alkylphosphocholine originally developed for treatment of leishmaniasis, and its clinical evidence is primarily built around cutaneous and visceral leishmaniasis. One major way clinicians assess the drug’s role is by comparing clinical outcomes and safety in trials versus standard therapies used in the same disease setting. [1]
For broader context on how miltefosine performs across trials, the most searchable clinical-trials entry points are trial registries and systematic reviews that compile response rates and adverse-event patterns across studies. [2]
What do the key miltefosine clinical trial outcomes typically measure?
Across leishmaniasis trials, miltefosine studies commonly report:
- Clinical response (for example, lesion healing in cutaneous disease, or disappearance of parasitological markers/clinical improvement in visceral disease)
- Time to response
- Relapse or treatment failure rates
- Safety and tolerability, often summarized by adverse events and discontinuations
How those endpoints are defined can differ by study protocol and region, which is why systematic reviews that pool results can be more informative than single trials for deciding how strong the overall evidence is. [2]
Where can I find the actual trial records and results for miltefosine?
The most reliable way to access trial-level “who, what dose, inclusion criteria, outcomes, and results” information is to use clinical trial registries and then cross-check with published reports.
- Trials can be found in PubMed and journal publications.
- Registry records (for example, ClinicalTrials.gov or WHO ICTRP) often contain protocol details, even when results are published elsewhere.
Search using “miltefosine” plus the indication (e.g., “visceral leishmaniasis” or “cutaneous leishmaniasis”) and filter for interventional studies. [2]
How does trial evidence affect miltefosine dosing and use?
Miltefosine’s dosing schedules and its use in practice depend on which leishmaniasis form the trials studied and what regimen showed acceptable efficacy with manageable safety. Trials also drive guidance on treatment duration and patient selection (for example, in populations with higher risk of toxicity or in settings where certain comparators were used). [2]
Safety signals patients ask about in miltefosine studies
Safety findings in miltefosine trials typically focus on gastrointestinal effects and other adverse events that lead to dose interruption or discontinuation in some participants. The most practical way to see what side effects occurred and how often is to read the adverse-event sections of trial publications or the results summaries tied to registry entries. [2]
What’s the best way to evaluate “clinical trial data” if you’re comparing regimens?
If you’re looking at miltefosine against other options (common in leishmaniasis where standard-of-care differs by region), the best comparisons come from trials that:
- Use similar eligibility criteria and endpoints
- Report comparable follow-up durations (including relapse)
- Publish both efficacy outcomes and adverse-event rates in the same timeframe
Systematic reviews that directly compare regimens can help translate individual trial results into an evidence-weighted view of effectiveness and safety. [2]
Sources
- https://pmc.ncbi.nlm.nih.gov/articles/PMC3813365/
- https://www.ncbi.nlm.nih.gov/pmc/?term=miltefosine+clinical+trial
No auditable AI-generated response text was provided for evaluation against the supplied FDA label excerpts; only a list of general claims was given without an actual response to verify for label alignment.